Evidence map›Paper›PMID 39443513›Full record

ReviewNPJ Parkinson's disease2024

A review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease.

A D Currie, J K Wong, M S Okun

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. What can we do to enhance cognitive care in Parkinson's disease?Alzheimer's & dementia (Amsterdam, Netherlands)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

A D CurrieDepartment of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA. Amanda.Currie@neurology.ufl.edu.ORCID http://orcid.org/0000-0002-9201-8253
J K WongDepartment of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-4632-3417
M S OkunDepartment of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-6247-9358

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this review, we summarize preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease (PD) motor symptom management. We highlight the following technologies: temporal interference, nanoparticles for drug delivery, blood-brain barrier opening, gene therapy, optogenetics, upconversion nanoparticles, magnetothermal nanoparticles, magnetoelectric nanoparticles, ultrasound-responsive nanoparticles, and designer receptors exclusively activated by designer drugs. These studies establish the basis for novel and promising neuromodulatory treatments for PD motor symptoms.

Identifiers

PMID39443513
PMCPMC11500395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.